financetom
Business
financetom
/
Business
/
IPO-bound Delhivery buys rival firm Spoton to strengthen B2B logistics capabilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IPO-bound Delhivery buys rival firm Spoton to strengthen B2B logistics capabilities
Aug 25, 2021 6:52 AM

Ahead of the IPO, homegrown logistics startup Delhivery is busy beefing up its business. The company on Tuesday announced the acquisition of its rival company Spoton for $200 million. This will give an exit as well as hefty returns to the Spoton investors - Samara capital and Xponential Fund Partners.

What does Spoton bring to the table for Delhivery?

The acquisition will enhance Delhivery's B2B express business capabilities. It will also provide synergistic benefits for the customers of the two delivery providers – Delhivery, as well as Spoton, with the B2B and B2C combination and, therefore, enhance the end-to-end supply chain capabilities.

Recently, Delhivery had collaborated with FedEx Express, which infused $100 million into the company and is also taking all these steps now to make the company more attractive for higher valuation in the IPO, which is underway.

The expected valuation of Delhivery by way of the IPO could be nearly $4 billion. The company is backed by marquee investors like Carlyle, SoftBank, and Tiger Global.

Delhivery had raised $275 million in May in a primary funding round led by Fidelity Management and Research Company. The funding took Delhivery's valuation to over $3 billion.

"This development is consistent with our objective of being growth-oriented and building scale in each of our business lines. Over 10 years, Delhivery has established a leading position in B2C logistics and now by combining our part truckload business with Spoton's we will be on the path to the same position in B2B express as well," Delhivery CEO Sahil Barua said.

Spoton Logistics managing director Abhik Mitra said the focus will continue to be on improving clients' businesses through investments in people, technology, network and infrastructure. "Our teams and our business partners will have an opportunity to be part of a much larger organisation with significant opportunities for growth," he said.

-With PTI inputs

For more, watch video

First Published:Aug 25, 2021 3:52 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
Jul 14, 2025
By Rishika Sadam July 14 (Reuters) - India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp. ( INCY ) The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by...
India orders its airlines to check fuel switches on Boeing jets
India orders its airlines to check fuel switches on Boeing jets
Jul 14, 2025
NEW DELHI, July 14 (Reuters) - The Indian aviation regulator on Monday ordered Indian airlines to examine fuel switches on Boeing ( BA ) aircraft, including the 787 and 737 models, to check for any malfunctions in their locking mechanism. The Directorate General of Civil Aviation said it had issued the order after several Indian and international airlines began making...
Ultragenyx Says Health Canada Extends Approval on Evkeeza to Treat Hypercholesterolemia
Ultragenyx Says Health Canada Extends Approval on Evkeeza to Treat Hypercholesterolemia
Jul 14, 2025
08:34 AM EDT, 07/14/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Monday that Health Canada expanded the approval of Evkeeza as an adjunct to diet and other low-density lipoprotein cholesterol-lowering therapies to treat children with homozygous familial hypercholesterolemia aged six months or older. The drug first received Health Canada approval in September 2023 as an adjunct to diet...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved